Today, SAVA’s stock has surged by almost 20%, approaching $80, despite the reality that it was just $39 a month ago. What is the company doing to develop the stock, and how far can it grow? And Should investors expect a $100 breakthrough in the coming months?
Recently, Cassava Sciences (SAVA) published encouraging interim data from the simufilam open-label study in February 2021. After six months of simufilam treatment, both patients’ cognitive and behavioral performance improved, with no safety concerns. Furthermore, Currently, Cassava Sciences has the rank of Zaks No. 3 (Retention).
Even before symptoms such as memory loss appear, a SavaDx blood test can detect Alzheimer’s disease. Even if the drug isn’t the blockbuster that shareholders are hoping for, if it succeeds, the stock might be a major winner. This stock is considered one of the fastest-growing by investors, who have high expectations for it. Every day, the stock sets up new price records, therefore it’s not too late to take advantage of this offer.